Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma – OncLive
OncLive |
Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma
OncLive IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% (95% CI, 46%-88%) for patients with heavily pretreated, advanced uveal melanoma, which is nearly double the historical expectations for patients with the disease, … |
